(Clonidine + naltrexone) is under clinical development by Allodynic Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect (Clonidine + naltrexone)’s likelihood of approval (LoA) and phase transition for Pain took place on 27 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Clonidine + naltrexone) Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

(Clonidine + naltrexone) overview

ATNC-05, a fixed dose combination of clonidine and naltrexone is under development for the treatment of chronic low back pain, emotional pain, and for the prevention of acute migraine. The combination therapy is administered orally. It acts by targeting alpha 2 adrenergic receptor, and toll like receptor 4. It was also under development for the treatment of trigerminal and postherpetic neuralgia.

Quick View (Clonidine + naltrexone) LOA Data

Report Segments
  • Innovator
Drug Name
  • (Clonidine + naltrexone)
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.